A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis
Plain Language Summary: What is the study about? Hemophilia A is a genetic bleeding disorder that causes bleeding for long periods because of lower than normal levels of factor VIII (FVIII), a protein that is important for blood clotting. FVIII replacement therapy is the typical approach to manage bleeds, but new and improved therapies are becoming widely available. Prophylaxis with the medication
